verve therapeutics stock ipo date

Get a real-time Verve Therapeutics Inc. Company profile page for Verve Therapeutics Inc including stock price company news press releases executives board members and contact information.

Ipo Investment Prospectus S 1

1458 000 00 First Day Return.

. On average they anticipate Verve Therapeutics stock price to reach 6233 in the next year. ET by Tomi Kilgore Verve started at neutral with 50 stock price target at JP. Get Verve Therapeutics Inc VERVNASDAQ real-time stock quotes news price and financial information from CNBC.

Stay up to date on the latest stock price chart news analysis fundamentals trading and investment tools. This description is not intended to be a recommendation to buy stock from this company. How to Invest in Verve after the IPO date opening price.

Their stock opened with 1900 in its Jun 16 2021 IPO. 1600 - 1800 per share. What is Verve IPO price range.

Their forecasts range from 3400 to 9200. Lock-Up Period Expiration Date. When is the Verve IPO date.

Verve Therapeutics has generated 840 earnings per share over the last year 840 diluted earnings per share. Available only to Subscribers. 24 2021 at 800 am.

VERV stock quote history news and other vital information to help you with your stock trading and investing. To see the companys full description view their prospectus. Verve Therapeutics Inc.

Verve Therapeutics Inc a genetic medicines company engages in developing gene editing medicines for patients to treat cardiovascular diseases. After the Massachusetts-based biotechnology companys upsized initial public offering priced above the expected range to value. Its lead product candidate is VERVE-101 a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.

ExEFF DATE TYPE CASH AMOUNT DECLARATION DATE RECORD DATE. Their latest funding was raised on Jan 19 2021 from a Series B round. The Verve IPO and stock trading.

Find the latest Verve Therapeutics Inc. First Filing Date Technology CPC Citations. In what currency Verve IPO and post-IPO shares will be traded.

Verve Therapeutics priced its IPO on June 16 2021 at 19 above its 16-to-18 range on 1404 million shares an increase from the 118 million shares in the prospectus to raise 2667 million. Verve Therapeutics started at hold with 58 stock price target at Stifel Nicolaus Sep. IPO Date Jun 17 2021.

Verve Therapeutics Priced Nasdaq. Verve intends to raise 201 million in gross proceeds from an IPO of its common stock offering 118 million shares at a proposed midpoint price of 1700 per share. VERV IPO Advisory and IPO Research from IPO Boutique.

The reported 065 earnings per share for the quarter missing analysts consensus estimates of 054 by 011. Verve Therapeutics VERV 080 is up 165 for the week. For a relatively.

Earnings Date 08122022est Ex Div Date-Div Amount-. Verve Therapeutics Stock Performance As of Friday Closing Stock Price Previous Close. Verve Therapeutics last announced its earnings data on March 14th 2022.

The Companyâs initial two programs target PCSK9 and ANGPTL3 respectively genes that regulate levels of blood lipids. Verve Therapeutics has raised a total of 2155M in funding over 3 rounds. View analysts price targets for Verve Therapeutics or view top-rated stocks among Wall Street analysts.

Verve Therapeutics is registered under the ticker NASDAQVERV. This suggests a possible upside of 3112 from the stocks current price. VERV Earnings Date and Information.

Find the latest Earnings Report Date for Verve Therapeutics Inc. After the IPO you can buy Verve stocks via Freedom24 or eToro on the first trading day. The company also engages in the development of ANGPTL3 program.

Preclinical biotech developing single-course gene editing therapies for cardiovascular disease. Common Stock VERV Nasdaq Listed. The Investor Relations website contains information about Verve Therapeuticss business for stockholders potential investors and financial analysts.

Is a genetic medicines company developing an approach to the care of cardiovascular disease CVD transforming treatment from chronic management to single-course gene editing medicines. A high-level overview of Verve Therapeutics Inc. The biotech stock which was as low as 4152 a share on Monday climbed as high as 4839 by Thursday.

In this study Verve observed potent and durable lowering of both blood PCSK9 protein and low-density lipoprotein cholesterol LDL-C levels of approximately 90 and 60 respectively following administration of a single gene editing treatment. Use the PitchBook Platform to explore the full profile. Information on stock financials earnings subsidiaries investors and executives for Verve Therapeutics.

VERV stock price quote with breaking news financials statistics charts and more. These data showed durability out to 10 months at the most recent analysis.

Beam

Sec Filing Verve Therapeutics

5 Lessons From Duolingo S Bellwether Edtech Ipo Of The Year Wilson S Media

Verve Therapeutics Nasdaqgs Verv Share Price News Analysis Simply Wall St

Verve Therapeutics Prepares 201 Million Ipo Pending Verv Seeking Alpha

How To Invest In Verve Ipo 2021

5 Potential Blockbuster Ipos To Add To Your Watch List The Motley Fool Initial Public Offering Marketing The Motley Fool

Duolingo

Sec Filing Verve Therapeutics

Ipo Outlook 2021 Saw Record Numbers But Poor Returns 2022 Looks Muted Scrip

Verve Therapeutics Prepares 201 Million Ipo Pending Verv Seeking Alpha

424b4

Ipo Investment Prospectus S 1

Verve Therapeutics Funding Financials Valuation Investors

Verve Therapeutics Announces 2022 Anticipated Milestones And Preclinical Data On Potential Additional Dosing Regimens For Its Novel Base Editing Programs